Want to see SE:ELIC full AI Analyst Report?

Elicera Therapeutics AB (ELIC) Price & Analysis

3 Followers

ELIC Stock Chart & Stats

kr5.35

kr0.03(1.27%)

At close: Mar 06 4:00 PM EST

kr5.35

kr0.03(1.27%)

Day’s Range― - ―

52-Week Rangekr2.25 - kr8.21

Previous CloseN/A

Volume204.65K

Average Volume (3M)134.24K

Market Cap

kr159.50M

Enterprise Valuekr239.86

Total Cash (Recent Filing)kr17.86M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.05

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding66,736,374

10 Day Avg. Volume92,396

30 Day Avg. Volume134,243

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.42

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free capital structure materially reduces mandatory interest and refinancing obligations, giving management flexibility on timing of fundraising and lowering near-term cash outflows. Over a 2–6 month horizon this improves survivability while R&D continues and limits interest-rate sensitivity relative to leveraged peers.

Favorable Gross Margin ProfileHigh gross margins when product revenue exists imply attractive unit economics and the potential for operating leverage as sales scale. Structurally, that supports durable margin expansion once clinical programs convert to commercial revenues or partnered deals, reducing long-term reliance on funding for every incremental sales dollar.

Focused Immuno-oncology PipelineConcentrated R&D in cell and gene therapies and CAR‑T aligns with strong, persistent industry demand for next‑generation oncology treatments. Having multiple preclinical and clinical assets creates several medium-term clinical and partnership inflection points, which is a durable strategic position if trials progress and external collaborations form.

Bears Say

High Cash BurnMaterial negative operating and free cash flows (~-27.8m TTM) indicate the company is heavily cash‑consumptive and will likely need external financing or deep cost cuts. Over a 2–6 month horizon this elevates dilution and refinancing risk, restricting strategic options and potentially slowing clinical progress if funding gaps emerge.

Weak And Falling RevenueVery low and sharply declining revenue (~2.7m TTM with ~751% decline) shows limited commercial traction and minimal internal cash generation to support R&D. Structurally, without recurring revenue growth or major non‑dilutive milestones, the company remains dependent on external funding to sustain operations and advance clinical programs.

Equity Erosion And Negative ROEPersistent losses producing a TTM ROE near -57% and falling equity signal ongoing dilution and capital base erosion. This undermines shareholder value and raises the probability of future equity raises that dilute holders, constraining long-term capital stability and complicating governance and strategic flexibility over the medium term.

ELIC FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was kr2.25 and its highest was kr8.21 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is kr159.50M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 16 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -kr0.102 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 66,736,374 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -kr0.102 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -32.414%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in SE:ELIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.